AZD6738 First Time in Patient Multiple Ascending Dose Study

Summary

In Part A to investigate the safety and tolerability of AZD6738 when given orally to patients with relapsed/refractory CLL, PLL or B cell lymphoma. In Part B to investigate the safety and tolerability of AZD6738 when given orally to patients with prospectively identified 11q deleted or ATM deficient, relapsed/refractory CLL

Timeline

Start

2013-11

Primary completion

2013-12

Completion

2013-12

Drugs

Indications